Efetividade e Segurança da Edoxabana nos Cuidados Clínicos de Rotina de Pacientes com Fibrilação Atrial no Brasil: Estudo Prospectivo de Acompanhamento de 1 Ano – EdoBRA
Rattachement africain : de, br, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Edoxaban, an orally administered anticoagulant, has been shown to be safe and effective in preventing stroke in atrial fibrillation (AF) patients. Given its widespread use since approval, evaluating edoxaban's real-world performance in the Brazilian clinical context is crucial. OBJECTIVE: The study aimed to report the one-year safety and effectiveness of edoxaban in AF patients in Brazil. METHODS: EdoBRA is a multi-center, prospective, observational investigation conducted across 30 Brazilian research sites. Bleeding events were considered as safety measures and cardiovascular events were considered for effectiveness measures. Descriptive analyses were performed. Kaplan-Meier curves were generated for time-to-event analysis and a 95% confidence interval was used as appropriate. RESULTS: Among the 705 enrolled participants, 590 were included in the analysis for having at least one follow-up or one reported event. Mean (±SD) CHA2DS2-VASc risk score was 3 (3.3 ± 1.6) and the mean HAS-BLED risk score was 2 (1.8 ± 1.2). During the one-year follow-up period, nine major bleedings events were reported, including five cases of gastrointestinal bleeding (IP 0.85 [95% CI =0.82; 0.88]). Among the cardiovascular events recorded (N = 68), there were four stroke events (IP 0.68 [CI 95% 0.65;0.71]), one transient ischemic attack (IP 0.17 [CI 95% (0.16;0.18]) and 1 event was Venous Thromboembolic Events (IP 0.17 [CI 95% (0.16;0.18]). No systemic embolic event was exhibited by any patient. CONCLUSION: In an elderly population with several comorbidities routinely treated with edoxaban for AF, the rates of cardiovascular event and major bleeding were low.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efetividade e Segurança da Edoxabana nos Cuidados Clínicos de Rotina de Pacientes com Fibrilação Atrial no Brasil: Estudo Prospectivo de Acompanhamento de 1 Ano – EdoBRA
- Date Crossref
- 01/01/2025
- Éditeur
- Sociedade Brasileira de Cardiologia
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Daiichi Sankyo (Germany) pays non établi dans la noticeEntreprise
-
Universidade Federal da Bahia pays non établi dans la noticeUniversité ou école supérieure
-
Hospital Ana Nery pays non établi dans la noticeÉtablissement de santé
-
Hospital do Coração pays non établi dans la noticeÉtablissement de santé
-
Beneficência Portuguesa de São Paulo pays non établi dans la noticeOrganisation à but non lucratif
-
Universidade de São Paulo pays non établi dans la noticeUniversité ou école supérieure
-
Universidade Regional de Blumenau pays non établi dans la noticeUniversité ou école supérieure
-
Instituto de Cardiologia de Santa Catarina pays non établi dans la noticeStructure de recherche
-
IQVIA (United Kingdom) pays non établi dans la noticeEntreprise
-
Pontifícia Universidade Católica de Campinas pays non établi dans la noticeUniversité ou école supérieure
-
Sociedade Hospitalar Angelina Caron pays non établi dans la noticeÉtablissement de santé
-
Daiichi Sankyo Brasil Farmaceutica LTDA pays non établi dans la noticeEntreprise
Daiichi Sankyo (Germany), Universidade Federal da Bahia et Hospital Ana Nery, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.